Pharvaris shares rose after the company disclosed positive topline data from a trial of a treatment for the genetic disorder hereditary angioedema $(HAE)$.

The stock gained 11% to $39.26 on Tuesday. Shares are up 48% over the past year.

The Swiss biopharmaceutical company said its Phase 3 trial evaluating deucrictibant extended-release tablets to prevent HAE attacks met its primary and secondary endpoints with statistical significance.

Data will serve as the basis for marketing authorization applications, which Pharvaris plans to submit starting in the first half of 2027.

The trial studied the tablet in adolescents and adults. Treatment reduced the mean monthly attack rate in patients with HAE by 83%. The drug was also well tolerated, with most adverse events being mild or moderate.

Pharvaris plans to submit a new drug application to the U.S. Food and Drug Administration for prophylaxis of bradykinin-mediated angioedema attacks in the first half of 2027.